Ali Ataripour Esfahani

Mr. Ali Ataripour Esfahani

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2023 in Livers
Verified
Journal Article
Open access
PDF file
BFBahareh Farasati Far
Bahareh Farasati Far
Ali Ataripour EsfahaniAli Ataripour Esfahani
Ali Ataripour Esfahani
ENElnaz Nasiriyan
Elnaz Nasiriyan
APAli Pourmolaei
Ali Pourmolaei
GMGolnaz Mahmoudvand
Golnaz Mahmoudvand
MNMohammad Reza Naimi-Jamal
Mohammad Reza Naimi-Jamal
More than 90% of all liver malignancies are hepatocellular carcinomas (HCCs), for which chemotherapy and immunotherapy are the ideal therapeutic choices. Hepatocellular carcinoma is descended from other liver diseases, such as viral hepatitis, alcoholism, and metabolic syndrome. Normal cells and tissues may suffer damage from common forms of chemotherapy. In contrast to systemic chemotherapy, localized chemotherapy can reduce side effects by delivering a steady stream of chemotherapeutic drugs directly to the tumor site. This highlights the significance of controlled-release biodegradable hydrogels as drug delivery methods for chemotherapeutics. This review discusses using hydrogels as drug delivery systems for HCC and covers thermosensitive, pH-sensitive, photosensitive, dual-sensitive, and glutathione-responsive hydrogels. Compared to conventional systemic chemotherapy, hydrogel-based drug delivery methods are more effective in treating cancer.